Phase III randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of PRM-151 in patients with idiopathic pulmonary fibrosis
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: ROCHE FARMA, SA
- Phase: III
- Execution start: 26/03/2021
- End of execution: 20/06/2023
- IP: ANA DOLORES ROMERO ORTIZ